Pancreatic Cancer Research

ResearcherWhitehead Institute for Biomedical ResearchActive in the last 2 years

Michael Lawrence Dougan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9266-2009; OpenAlex author ID A5043698578; NIH RePORTER profile ID 12311821. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
1
Labs led
0
Collaborators
38
Papers, trials and grants by year

2015: 1 paper · 2016: 1 grant · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 6

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  3. Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. Co-author DOI 10.1093/immadv/ltag013↗
  4. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  5. Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. Co-author DOI 10.1053/j.gastro.2023.05.038↗
  6. The use of 18F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. Co-author DOI 10.1021/acscentsci.5b00121↗

Grants 1

  1. Targeting cytokines to the tumor microenivronment using a high affinity single domain antibody to PD-L1 F32CA210568↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stephanie K. Dougan · 5 shared papers, 2023–2026 · strength 1.01
  2. Megan T. Hoffman · 3 shared papers, 2023–2026 · strength 0.69
  3. Andrew J. Aguirre · 3 shared papers, 2023–2026 · strength 0.69
  4. Brendan D. Parent · 2 shared papers, 2026 · strength 0.54
  5. Harshabad Singh · 3 shared papers, 2024–2026 · strength 0.51
  6. Douglas Adam Rubinson · 3 shared papers, 2024–2026 · strength 0.51
  7. Brian Matthew Wolpin · 3 shared papers, 2024–2026 · strength 0.51
  8. Brandon M. Huffman · 3 shared papers, 2024–2026 · strength 0.51
  9. Jonathan Andrew Nowak · 3 shared papers, 2024–2026 · strength 0.51
  10. Kimberly J. Perez · 3 shared papers, 2024–2026 · strength 0.51
  11. James M. Cleary · 3 shared papers, 2024–2026 · strength 0.51
  12. Victoire Cardot‐Ruffino · 3 shared papers, 2023–2026 · strength 0.47
  13. Lestat R. Ali · 3 shared papers, 2023–2026 · strength 0.47
  14. Courtney T.S. Kureshi · 2 shared papers, 2026 · strength 0.38
  15. Chong Zuo · 2 shared papers, 2026 · strength 0.38
  16. George Molina · 2 shared papers, 2026 · strength 0.38
  17. Thomas E. Clancy · 2 shared papers, 2026 · strength 0.38
  18. Joseph Douglas Mancias · 2 shared papers, 2026 · strength 0.38
  19. Marc R. Pelletier · 2 shared papers, 2023–2024 · strength 0.28
  20. Qiang Li · 1 shared paper, 2026 · strength 0.19
  21. Qiang Li · 1 shared paper, 2023 · strength 0.14
  22. Viviana Cremasco · 1 shared paper, 2023 · strength 0.14
  23. Srivatsan Raghavan · 1 shared paper, 2023 · strength 0.14
  24. Annan Yang · 1 shared paper, 2023 · strength 0.14
  25. Dafna Bar‐Sagi · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.